Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
SPRY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.34 - $18.90
Previous CloseN/A
Volume456.05K
Average Volume (3M)3.23M
Market Cap
$1.01B
Enterprise Value$1.48B
Total Cash (Recent Filing)$275.73M
Total Debt (Recent Filing)$73.00K
Price to Earnings (P/E)174.1
Beta1.30
Next Earnings
Nov 06, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding98,826,340
10 Day Avg. Volume2,949,152
30 Day Avg. Volume3,229,413
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.46
Enterprise Value/Revenue15.22
Enterprise Value/Gross Profit15.55
Enterprise Value/Ebitda-58.26
Forecast
1Y Price Target
$31.00Price Target Upside201.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe publication shares real-world evidence evaluating the performance of neffy in 545 patients experiencing anaphylaxis symptoms during oral food allergy challenge and allergen immunotherapy.
Consumer AdoptionIn the latest consumer survey, 93% of patients were at least 'very likely to consider' neffy if their healthcare provider recommended it, with 68% being 'extremely likely to consider,' suggesting the potential for strong adoption with broad awareness.
Market ExpansionNeffy approval in Japan expands the geographic reach of the product, which is already available in the U.S. and Germany and has recently received approval in the U.K.
Bears Say
Prescription ChallengesEnding the GoodRx program has been a headwind for weekly script numbers that have underwhelmed investors in recent weeks; however, this should have minimal impact on revenue.
Regulatory ChallengesThe citizen petition filed by ARS against the approval of Anaphylm highlights potential issues in its data that could prevent its approval or limit its commercial adoption if approved.
Share Price DeclineThe weakness in shares of ARS in recent weeks, down over 40% since its highs in July, is considered unwarranted despite facing some headwinds.
ARS Pharmaceuticals News
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $9.34 and its highest was $18.90 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
ARS Pharmaceuticals’s market cap is $1.01B.
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 29 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Aug 13, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.458 by -$0.002.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -0.46.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 98,826,340 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.458. Following the earnings report the stock price went down -5.042%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Currently, no hedge funds are holding shares in SPRY
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (201.85% Upside)
$31.00 (201.85% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 789.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 16.6%
Last 30 Days ▲ 40.8%
Last 30 Days ▲ 40.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.62%
12-Months-Change
Fundamentals
Return on Equity
-23.56%
Trailing 12-Months
Asset Growth
41.23%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
SPRY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant growth in revenue and prescription volume for Neffy, along with expanded global presence and commercial coverage. However, high SG&A expenses and ongoing challenges with prior authorization requirements present some concerns. The positive aspects of the call, particularly the strong revenue growth and strategic global expansion, outweigh the lowlights.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$31.00
▲(201.85% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
69.65% Insiders
10.15% Mutual Funds
0.16% Other Institutional Investors
11.49% Public Companies and
Individual Investors